摘要
目的探讨重组人干扰素α-1b联合氨溴索治疗小儿支气管肺炎的效果及对炎症因子的影响。方法选取2022年5月至2023年7月蒲城县医院儿科收治的100例支气管肺炎患儿为研究对象,采用随机数字表法分为A组、B组、C组、D组,每组25例。A组给予常规治疗,B组在A组基础上给予重组人干扰素α-1b治疗,C组在A组基础上给予氨溴索治疗,D组在A组基础上给予重组人干扰素α-1b联合氨溴索治疗;比较4组治疗效果。结果D组治疗总有效率高于A、B组,差异有统计学意义(P<0.05);治疗后,D组炎症因子水平低于A、B、C组,差异有统计学意义(P<0.05);四组患儿的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论重组人干扰素α-1b联合氨溴索治疗小儿支气管肺炎的效果显著,能够降低炎症因子水平,值得推广。
Objective To explore the effect of Recombinant Human Interferonα-1b combined with Ambroxol in the treatment of children with bronchopneumonia and its influence on inflammatory factors.Methods A total of 100 children with bronchopneumonia in Department of Pediatrics,Pucheng County Hospital from May 2022 to July 2023 were selected and divided into group A,group B,group C and group D by the random number table method,with 25 cases in each group.The group A was given conventional treatment,while the group B was given Recombinant Human Interferonα-1b on the basis of group A,the group C was given Ambroxol on the basis of group A,the group D was given Recombinant Human Interferonα-1b combined with Ambroxol on the basis of group A.The treatment effect of the four groups was compared.Results The total effective rate of group D was higher than that of group A and B,the difference was statistically significant(P<0.05).After treatment,the levels of inflammatory factors in group D were lower than those in group A,B,and C,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions among the four groups(P>0.05).Conclusion Recombinant Human Interferonα-1b combined with Ambroxol in the treatment of children with bronchopneumonia has significant effect,which can reduce the level of inflammatory factors and is worth promoting.
作者
白欣
BAI Xin(Department of Pediatrics,Pucheng County Hospital,Shaanxi Province,Pucheng 715500,China)
出处
《妇儿健康导刊》
2023年第24期129-132,共4页
JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE
关键词
重组人干扰素Α-1B
氨溴索
小儿支气管肺炎
炎症因子
Recombinant Human Interferonα-1b
Ambroxol
Children with bronchopneumonia
Inflammatory factor
